DermaGen Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

DermaGen General Information

Description

Developer of antimicrobial peptides directed against skin microbes. The company develops peptides which exert potent antimicrobial effects and are derived from endogenous human proteins, such as those of the complement system, as well as several other skin and blood-derived proteins.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Scheelevägen 22
  • SE-223 63 Lund
  • Sweden
+46 046-19
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Acquirer
Corporate Office
  • Scheelevägen 22
  • SE-223 63 Lund
  • Sweden
+46 046-19

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

DermaGen Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 01-Dec-2010 Completed Generating Revenue
2. Early Stage VC 02-Apr-2008 Completed Startup
1. Corporate Completed Startup
To view DermaGen’s complete valuation and funding history, request access »

DermaGen Patents

DermaGen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2012033450-A1 Novel antimicrobial peptides Inactive 07-Sep-2010
ES-2476590-T3 Enhanced antimicrobial peptides Active 16-May-2006
WO-2007133153-A1 Improved antimicrobial peptides Inactive 16-May-2006
WO-2007133153-A8 Improved antimicrobial peptides Inactive 16-May-2006
CA-2637216-A1 Novel antimicrobial peptides and use thereof Inactive 10-Feb-2006 C07K14/4723
To view DermaGen’s complete patent history, request access »

DermaGen Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Granitor Venture Capital Minority
KDventures Venture Capital Minority
LU Ventures (Lund) Corporate Venture Capital Minority
Östersjöstiftelsen Limited Partner Minority
To view DermaGen’s complete investors history, request access »

DermaGen Investments (1)

DermaGen’s most recent deal was a Early Stage VC with XImmune for . The deal was made on 01-Jan-2009.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
XImmune 01-Jan-2009 Early Stage VC Drug Discovery
To view DermaGen’s complete investments history, request access »

DermaGen FAQs

  • When was DermaGen founded?

    DermaGen was founded in 2004.

  • Where is DermaGen headquartered?

    DermaGen is headquartered in Lund, Sweden.

  • What industry is DermaGen in?

    DermaGen’s primary industry is Drug Discovery.

  • Is DermaGen a private or public company?

    DermaGen is a Private company.

  • What is DermaGen’s current revenue?

    The current revenue for DermaGen is .

  • How much funding has DermaGen raised over time?

    DermaGen has raised $1.56M.

  • Who are DermaGen’s investors?

    Granitor, KDventures, LU Ventures (Lund), and Östersjöstiftelsen have invested in DermaGen.

  • When was DermaGen acquired?

    DermaGen was acquired on 01-Dec-2010.

  • Who acquired DermaGen?

    DermaGen was acquired by Pharmasurgics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process